<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599064</url>
  </required_header>
  <id_info>
    <org_study_id>RXI-109-1501</org_study_id>
    <nct_id>NCT02599064</nct_id>
  </id_info>
  <brief_title>Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD</brief_title>
  <official_title>A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RXi Pharmaceuticals, Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RXi Pharmaceuticals, Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109
      administered by intravitreal injection to reduce the progression of subretinal fibrosis in
      subjects with advanced neovascular age-related macular degeneration (NVAMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple doses of
      RXI-109 when administered by intravitreal injection. Evaluate the clinical activity of single
      and multiple doses of RXI-109 when administered by intravitreal injection. Study
      participation is intended to be seven months from time of initial treatment with RXI-109.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity and relationship of AEs, including clinically significant changes in physical examination findings, ocular examinations and assessments, and clinical laboratory results</measure>
    <time_frame>Seven (7) months</time_frame>
    <description>Assess severity and frequency of reported adverse events graded by CTCAE, ophthalmological exams to assess clinically relevant changes in ocular health, clinically-relevant changes in physical exams or laboratory testing assessed by medical personnel, and monitoring for any change in best corrected visual acuity (BCVA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of RXI-109 in blood</measure>
    <time_frame>Four (4) months</time_frame>
    <description>Determine systemic exposure (AUC) of RXI-109 after intra-ocular injections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change (%) of subretinal fibrosis lesion size compared to baseline using standard ophthalmologic imaging.</measure>
    <time_frame>Seven (7) months</time_frame>
    <description>Evaluate the clinical activity of RXI-109 to reduce the formation or progression of subretinal fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in BCVA using the Early Treatment Diabetic Retinopathy (ETDRS) chart</measure>
    <time_frame>Seven (7) months</time_frame>
    <description>Evaluate the clinical activity of RXI-109 by assessing changes in visual acuity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relative change (%) of CTGF protein levels in aqueous fluid compared to baseline</measure>
    <time_frame>Seven (7) months</time_frame>
    <description>Evaluate the clinical activity of RXI-109 by assessing changes in CTGF protein levels in aqueous fluid</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Subfoveal Choroidal Neovascularization</condition>
  <condition>Subretinal Scarring</condition>
  <condition>Subretinal Fibrosis</condition>
  <arm_group>
    <arm_group_label>RXI-109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXI-109</intervention_name>
    <description>RXI-109 dosed intravitreally to subjects with NVAMD</description>
    <arm_group_label>RXI-109</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects presenting with advanced NVAMD in the study eye with BCVA ≤20/100 potentially
             due to subretinal fibrosis involving the fovea

          -  BCVA ≥20/800 in the contralateral eye and better than the study eye

          -  ≥50 years of age

          -  Subfoveal choroidal neovascularization (CNV) of any type

        Exclusion Criteria:

          -  Presence of other causes of CNV including pathologic myopia, ocular histoplasmosis
             syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis

          -  Evidence of inflammation (Grade 1 or higher) in the anterior or posterior chamber
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerrit Dispersyn</last_name>
    <role>Study Director</role>
    <affiliation>RXi Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>RXI-109</keyword>
  <keyword>NVAMD</keyword>
  <keyword>Retinal scarring</keyword>
  <keyword>Subretinal scarring</keyword>
  <keyword>Retinal fibrosis</keyword>
  <keyword>Subretinal fibrosis</keyword>
  <keyword>Eye diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

